tm logo
MEZMIRIG
ADVERTISED

on 13 Nov 2024

Last Applicant/ Owned by

Celgene Corporation

Route 206 & Province Line RoadPrinceton, NJ 08543

US

Serial Number

2145636 filed on 08th Nov 2021

Correspondent Address

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

MEZMIRIG

Trademark usage description

pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosi Read More

Classification Information


Class [005]
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use; radiopharmaceuticals;


Classification kind code

11

Mark Details


Serial Number

2145636

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 42
on 13th Nov 2024
Advertised
Submitted for opposition 26
on 17th Oct 2024
Approved
Submitted for opposition 27
on 17th Oct 2024
Approval Notice Sent
Submitted for opposition 20
on 13th Aug 2024
Examiner's First Report
Submitted for opposition 22
on 12th Aug 2024
Search Recorded
Submitted for opposition 135
on 21st Mar 2024
Amendment to Application
Submitted for opposition 287
on 17th May 2022
Pre-Assessment Letter Sent
Submitted for opposition 30
on 08th Nov 2021
Filed
Submitted for opposition 1
on 08th Nov 2021
Created
Submitted for opposition 31
on 08th Nov 2021
Formalized